|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Transarterial chemoembolization and bland embolization for hepatocellular carcinoma显示文摘Transarterial chemoembolization(TACE)is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth.Despite its widespread use,TACE remains an unstandardized procedure,with variation in type and size of embolizing particles,type and dose of chemotherapy and interval between therapies.Existing evidence from randomized controlled trials suggest that bland transarterial embolization(TAE)has the same efficacy with TACE.In the current article,we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use. | Emmanuel A Tsochatzis Evangelia Fatourou James O'Beirne Tim Meyer Andrew K Burroughs | 2014 | World Journal of Gastroenterology2014，20，12： | 18 |
| 2 | Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease显示文摘Alcoholic liver disease(ALD) consists of a broad spectrum of disorders, ranging from simple steatosisto alcoholic steatohepatitis and cirrhosis. Fatty liver develops in more than 90% of heavy drinkers, however only 30%-35% of them develop more advanced forms of ALD. Therefore, even if the current 'gold standard' for the assessment of the stage of alcohol-related liver injury is histology, liver biopsy is not reasonable in all patients who present with ALD. Currently, although several non-invasive fibrosis markers have been suggested as alternatives to liver biopsy in patients with ALD, none has been sufficiently validated. As described in other liver disease, the diagnostic accuracy of such tests in ALD is acceptable for the diagnosis of significant fibrosis or cirrhosis but not for lesser fibrosis stages. Existing data suggest that the use of noninvasive tests could be tailored to first tier screening of patients at risk, in order to diagnose early patients with progressive liver disease and offer targeted interventions for the prevention of decompensation. We review these tests and critically appraise the existing evidence. | Rosa Lombardi Elena Buzzetti Davide Roccarina Emmanuel A Tsochatzis | 2015 | World Journal of Gastroenterology2015，21，39： | 13 |
| 3 | Liver cirrhosis显示文摘 | Emmanuel A Tsochatzis Jaime Bosch Andrew K Burroughs | 2014 | The Lancet2014，，： | 9 |
| 4 | Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis显示文摘AIM:To investigate the adipokine levels of leptin,adiponectin,resistin,visfatin,retinol-binding protein 4(RBP4),apelin in alcoholic liver cirrhosis(ALC).METHODS:Forty non-diabetic ALC patients[median age:59 years,males:35(87.5%),Child-Pugh(CP)score:median 7(5-12),CP A/B/C:18/10/12,Model for End-stage Liver Disease(MELD):median 10(6-25),follow-up:median 32.5 mo(10-43)]were prospectively included.The serum adipokine levels were estimated in duplicate by ELISA.Somatometric characteristics were assessed with tetrapolar bioelectrical impedance analysis.Pearson’s rank correlation coefficient was used to assess possible associations with adipokine levels.Univariate and multivariate Cox regression analysis was used to determine independent predictors for overallsurvival.RESULTS:Body mass index:median 25.9(range:20.1-39.3),fat:23.4%(7.6-42.1),fat mass:17.8(5.49-45.4),free fat mass:56.1(39.6-74.4),total body water(TBW):40.6(29.8-58.8).Leptin and visfatin levels were positively associated with fat mass(P<0.001/P=0.027,respectively)and RBP4 with TBW(P=0.025).Median adiponectin levels were significantly higher in CPC compared to CPA(CPA:7.99±14.07,CPB:7.66±3.48,CPC:25.73±26.8,P=0.04),whereas median RBP4 and apelin levels decreased across the spectrum of disease severity(P=0.006/P=0.034,respectively).Following adjustment for fat mass,visfatin and adiponectin levels were significantly increased from CPA to CPC(both P<0.001),whereas an inverse correlation was observed for both RBP4 and apelin(both P<0.001).In the multivariate Cox regression analysis,only MELD had an independent association with overall survival(HR=1.53,95%CI:1.05-2.32;P=0.029).CONCLUSION:Adipokines are associated with deteriorating liver function in a complex manner in patients with alcoholic liver cirrhosis. | Maria Kalafateli Christos Triantos Emmanuel Tsochatzis Marina Michalaki Efstratios Koutroumpakis Konstantinos Thomopoulos Venetsanea Kyriazopoulou Eleni Jelastopulu Andrew Burroughs Chryssoula Lambropoulou-Karatza Vasiliki Nikolopoulou | 2015 | World Journal of Gastroenterology2015，21，10： | 8 |
| 5 | Reduced Exposure to Calcineurin Inhibitors Early After Liver Transplantation Prevents Recurrence of Hepatocellular Carcinoma显示文摘 | Manuel Rodríguez-Perálvarez Emmanuel Tsochatzis María Carmen Naveas Giulia Pieri Carmen García-Caparrós James O’Beirne Antonio Poyato-González Gustavo Ferrín-Sánchez Jose Luis Montero-álvarez David Patch Douglas Thorburn Javier Brice?o Manuel De la Mata A | 2013 | Journal of Hepatology2013，，： | 5 |
| 6 | Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy显示文摘 | E.A. Tsochatzis K.S. Gurusamy S. Ntaoula E. Cholongitas B.R. Davidson A.K. Burroughs | 2010 | Journal of Hepatology2010，，4： | 5 |
| 7 | Is there any progress in the treatment of non-alcoholic fatty liver disease?显示文摘Despite the fact that non-alcoholic fatty liver disease(NAFLD) and its severe clinical form,non-alcoholic steatohepatitis,are becoming increasingly prevalent in the industrialised countries,there are no licensed pharmacological treatments for them.Weight loss and life modifications,antioxidant therapies and insulin-sensitising agents are the current treatment strategies and have all been tested with inconclusive results.Low sample numbers,inadequate treatment duration and invalid surrogate markers for treatment response might all account for these results.As NAFLD is a systemic rather than a liver disease,future trials should address the patient as a whole and also address cardiovascular risk factors. | Emmanuel A Tsochatzis George V Papatheodoridis | 2011 | World Journal of Gastrointestinal Pharmacology and Therapeutics2011，2，1： | 4 |
| 8 | Renal failure and cirrhosis: A systematic review of mortality and prognosis显示文摘 | Giuseppe Fede Gennaro D’Amico Vasiliki Arvaniti Emmanuel Tsochatzis Giacomo Germani Dimosthenis Georgiadis Alberto Morabito Andrew Kenneth Burroughs | 2011 | Journal of Hepatology2011，，4： | 4 |
| 9 | Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy显示文摘 | Emmanuel A. Tsochatzis George V. Papatheodoridis Athanasios J. Archimandritis Fulvio D’Acquisto | 2009 | Mediators of Inflammation2009，，： | 2 |
| 10 | Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis显示文摘 | Marco Senzolo Teresa M. Sartori Valeria Rossetto Patrizia Burra Umberto Cillo Patrizia Boccagni Daniele Gasparini Diego Miotto Paolo Simioni Emmanuel Tsochatzis Kenneth A. Burroughs | 2012 | Liver Int2012，，6： | 2 |
| 11 | Gastrointestinal bleeding:Carvedilol-the best beta-blocker for primary prophylaxis显示文摘 | Tsochatzis EA Triantos CK Burroughs AK | 2009 | Nat Rev Gastroenterol Hepatol2009，6，12： | 1 |
| 12 | Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity 显示文摘 | Tsochatzis E Papatheodoridis G V Hadziyannis E | 2008 | Seand J Gastroenterol2008，43，9： | 1 |
| 13 | Gastro- intestinal bleeding: carvedilol - the best beta - blocker for pri- mary prophylaxis? 显示文摘 | TSOCHATZIS EA TRIANTOS CK BURROUGHS AK | 2009 | Nat Rev Gastroenterol Hepatol2009，6，12： | 1 |
| 14 | Predicting severity and clinical course of acute rejection af/er liver transplantation using blood eosinophil count 显示文摘 | Rodriguez-Peralvarez M Germani G Tsochatzis E | 2012 | Transpl Int2012，25，5： | 1 |
| 15 | Adipokines in nonalcoholic steatohepatitis: fi:om pathogenesis to implications in diagnosis and therapy显示文摘 | Tsochatzis EA Papatheodoridis GV Archimandritis AJ | 2009 | Mediators lnflamm2009，2009，83： | 1 |
| 16 | Systematic review:portal vein thrombosis in cirrhosis显示文摘 | Tsochatzis EA Senzolo M Germani G | | 0，，3： | 1 |
| 17 | Liver cirrho-sis显示文摘 | Tsochatzis E A Bosch J Burroughs A K | 2014 | Lancet2014，383，9930： | 1 |
| 18 | Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis显示文摘 | Emmanuel Tsochatzis Sara Bruno Graziella Isgro Andrew Hall Eleni Theocharidou Pinelopi Manousou Amar P. Dhillon Andrew K. Burroughs Tu Vinh Luong | 2013 | Journal of Hepatology2013，，： | 1 |
| 19 | Liver cirrhosis显示文摘 | Tsochatzis EA Bosch J Burroughs AK | 2014 | Lancet2014，383，9930： | 1 |
| 20 | Liver cirrhosis显示文摘 | Tsochatzis EA Bosch J Burroughs A K | 2014 | Lancet2014，383，9930： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员